Design and rationale for the Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study: A multicenter, prospective, randomized, single-blind trial comparing early and late intracoronary or combined (percutaneous intramyocardial and intracoronary) administration of nonselected autologous bone marrow cells to patients after acute myocardial infarction.
Nyolczas, Noemi MD, FESC a,b; Gyongyosi, Mariann MD a; Beran, Gilbert MD a; Dettke, Markus MD c; Graf, Senta MD a; Sochor, Heinz MD, FESC a; Christ, Gunther MD a; Edes, Istvan MD, PhD, FESC d; Balogh, Laszlo MD d; Krause, Korff T. MD e; Jaquet, Kai MD e; Kuck, Karl-Heinz MD e; Benedek, Imre MD f; Hintea, Theodora MD f; Kiss, Robert MD, PhD b; Preda, Istvan MD, PhD, FESC b; Kotevski, Vladimir MD, FESC g; Pejkov, Hristo MD g; Dudek, Darius MD h; Heba, Grzegorz MD h; Sylven, Christer MD i; Charwat, Silvia MD a; Jacob, Ronaldo MD a; Maurer, Gerald MD, FACC a; Lang, Irene MD a; Glogar, Dietmar MD, FESC a
American Heart Journal.
153(2):212e1-212e7, February 2007.
(Format: HTML, PDF)